126 related articles for article (PubMed ID: 28797197)
41. Downregulation of Skp2 and p27/Kip1 synergistically induces apoptosis in T98G glioblastoma cells.
Lee SH; McCormick F
J Mol Med (Berl); 2005 Apr; 83(4):296-307. PubMed ID: 15605273
[TBL] [Abstract][Full Text] [Related]
42. Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer.
Chiappetta G; De Marco C; Quintiero A; Califano D; Gherardi S; Malanga D; Scrima M; Montero-Conde C; Cito L; Monaco M; Motti ML; Pasquinelli R; Agosti V; Robledo M; Fusco A; Viglietto G
Endocr Relat Cancer; 2007 Jun; 14(2):405-20. PubMed ID: 17639054
[TBL] [Abstract][Full Text] [Related]
43. Proteomic identification of the oncoprotein STAT3 as a target of a novel Skp1 inhibitor.
Cheng X; Liu YQ; Wang GZ; Yang LN; Lu YZ; Li XC; Zhou B; Qu LW; Wang XL; Cheng YX; Liu J; Tao SC; Zhou GB
Oncotarget; 2017 Jan; 8(2):2681-2693. PubMed ID: 27835873
[TBL] [Abstract][Full Text] [Related]
44. Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells.
Bhatt KV; Hu R; Spofford LS; Aplin AE
Oncogene; 2007 Feb; 26(7):1056-66. PubMed ID: 16924241
[TBL] [Abstract][Full Text] [Related]
45. Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.
Iskandarani A; Bhat AA; Siveen KS; Prabhu KS; Kuttikrishnan S; Khan MA; Krishnankutty R; Kulinski M; Nasr RR; Mohammad RM; Uddin S
J Transl Med; 2016 Mar; 14():69. PubMed ID: 26956626
[TBL] [Abstract][Full Text] [Related]
46. Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer.
Hershko DD
Cancer; 2008 Apr; 112(7):1415-24. PubMed ID: 18260093
[TBL] [Abstract][Full Text] [Related]
47. Overexpression of Skp2 in carcinoma of the cervix does not correlate inversely with p27 expression.
Dowen SE; Scott A; Mukherjee G; Stanley MA
Int J Cancer; 2003 Jun; 105(3):326-30. PubMed ID: 12704665
[TBL] [Abstract][Full Text] [Related]
48. The Skp2 Pathway: A Critical Target for Cancer Therapy.
Cai Z; Moten A; Peng D; Hsu CC; Pan BS; Manne R; Li HY; Lin HK
Semin Cancer Biol; 2020 Dec; 67(Pt 2):16-33. PubMed ID: 32014608
[TBL] [Abstract][Full Text] [Related]
49. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation.
Huang H; Regan KM; Wang F; Wang D; Smith DI; van Deursen JM; Tindall DJ
Proc Natl Acad Sci U S A; 2005 Feb; 102(5):1649-54. PubMed ID: 15668399
[TBL] [Abstract][Full Text] [Related]
50. Skp2 promotes adipocyte differentiation via a p27Kip1-independent mechanism in primary mouse embryonic fibroblasts.
Okada M; Sakai T; Nakamura T; Tamamori-Adachi M; Kitajima S; Matsuki Y; Watanabe E; Hiramatsu R; Sakaue H; Kasuga M
Biochem Biophys Res Commun; 2009 Feb; 379(2):249-54. PubMed ID: 19109928
[TBL] [Abstract][Full Text] [Related]
51. Chemical probes of Skp2-mediated p27 ubiquitylation and degradation.
Lough L; Sherman D; Ni E; Young LM; Hao B; Cardozo T
Medchemcomm; 2018 Jul; 9(7):1093-1104. PubMed ID: 30108998
[TBL] [Abstract][Full Text] [Related]
52. Skp2 regulates the antiproliferative function of the tumor suppressor RASSF1A via ubiquitin-mediated degradation at the G1-S transition.
Song MS; Song SJ; Kim SJ; Nakayama K; Nakayama KI; Lim DS
Oncogene; 2008 May; 27(22):3176-85. PubMed ID: 18071316
[TBL] [Abstract][Full Text] [Related]
53. Skp2 protein expression in soft tissue sarcomas.
Oliveira AM; Okuno SH; Nascimento AG; Lloyd RV
J Clin Oncol; 2003 Feb; 21(4):722-7. PubMed ID: 12586812
[TBL] [Abstract][Full Text] [Related]
54. Skp2: A critical molecule for ubiquitination and its role in cancer.
Feng T; Wang P; Zhang X
Life Sci; 2024 Feb; 338():122409. PubMed ID: 38184273
[TBL] [Abstract][Full Text] [Related]
55. E3-ligase Skp2 regulates β-catenin expression and maintains hematopoietic stem cell homing.
Wang J; Han F; Lee SW; Wu J; Chan CH; Zhang X; Gao Y; Su HK; Feng ZZ; Xu DZ; Lin HK
Biochem Biophys Res Commun; 2014 Mar; 445(3):566-71. PubMed ID: 24561244
[TBL] [Abstract][Full Text] [Related]
56. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis.
Chan CH; Li CF; Yang WL; Gao Y; Lee SW; Feng Z; Huang HY; Tsai KK; Flores LG; Shao Y; Hazle JD; Yu D; Wei W; Sarbassov D; Hung MC; Nakayama KI; Lin HK
Cell; 2012 May; 149(5):1098-111. PubMed ID: 22632973
[TBL] [Abstract][Full Text] [Related]
57. Skp2 stabilizes Mcl-1 and confers radioresistance in colorectal cancer.
Yu X; Zhou L; Liu W; Liu L; Gao F; Li W; Liu H
Cell Death Dis; 2022 Mar; 13(3):249. PubMed ID: 35301297
[TBL] [Abstract][Full Text] [Related]
58. SKP2 promotes the metastasis of pancreatic ductal adenocarcinoma by suppressing TRIM21-mediated PSPC1 degradation.
Yuan J; Zhu Z; Zhang P; Ashrafizadeh M; Abd El-Aty AM; Hacımüftüoğlu A; Linnebacher CS; Linnebacher M; Sethi G; Gong P; Zhang X
Cancer Lett; 2024 Apr; 587():216733. PubMed ID: 38360141
[TBL] [Abstract][Full Text] [Related]
59. SKP2 targeted inhibition suppresses human uveal melanoma progression by blocking ubiquitylation of p27.
Zhao H; Pan H; Wang H; Chai P; Ge S; Jia R; Fan X
Onco Targets Ther; 2019; 12():4297-4308. PubMed ID: 31213847
[No Abstract] [Full Text] [Related]
60. Virtual drug design: Skp1-Skp2 inhibition targets cancer stem cells.
Pascal LE; Wang Z
Asian J Androl; 2013 Nov; 15(6):717-8. PubMed ID: 24077600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
